Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1Gynecologic 1

Conditions

Vomiting 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 244Nivolumab 140Cisplatin 135Cyclophosphamide 134Paclitaxel 113Carboplatin 108Gemcitabine 98Radiotherapy 83Dexamethasone 83Docetaxel 77atezolizumab 68Ipilimumab 68Doxorubicin 62Fluorouracil 60Blood Specimen Collection 58Bevacizumab 58fludarabine 54Rituximab 54Etoposide 53Oxaliplatin 52Surveys and Questionnaires 49Lenalidomide 49Prednisone 47Standard of Care 45Magnetic Resonance Spectroscopy 45Cetuximab 44Capecitabine 44lenvatinib 43Radiosurgery 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Aprepitant × 1 year × Clear all
NCT06007586 2025-12-04

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

Sichuan Cancer Hospital and Research Institute

Phase 3 Completed
143 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Vomiting, Endometrial Neoplasms

NCT03808805 2025-12-03

APHYPAP

University Hospital, Brest

Phase 3 Completed
63 enrolled
Myeloid

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡